FDA
-
-
-
-
-
-
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
-
-
-
-
-
-
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
2025 Biopharma sector outlook
-
-
-
-
-
-
-
CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook
-
-
-
-
-
-
-
Vertex Pharma (VRTX) and CRISPR Therapeutics (CRSP) Announce Authorization of the CASGEVY in the UK
-
-
-
-
-
-
-
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Th
-
327,617 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

